Brickell Biotech Inc BBI:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 12:00 PM EST
1.17quote price arrow down-0.01 (-0.85%)
Volume
1,654,694
52 week range
0.47 - 3.00

...

Loading . . .

KEY STATS

  • Open1.16
  • Day High1.18
  • Day Low1.03
  • Prev Close1.18
  • 52 Week High3.00
  • 52 Week High Date03/04/20
  • 52 Week Low0.47
  • 52 Week Low Date11/04/20
  • Market Cap62.62M
  • Shares Out53.52M
  • 10 Day Average Volume2.65M
  • Dividend-
  • Dividend Yield-
  • Beta0.17
  • 1 Year % Change-58.54

RATIOS/PROFITABILITY

  • EPS (TTM)-2.40
  • P/E (TTM)-0.49
  • Fwd P/E (NTM)-2.85
  • EBITDA (MRQ)-21.404M
  • ROE (MRQ)-132.17%
  • Revenue (MRQ)2.46M
  • Gross Margin (MRQ)0.00%
  • Net Margin (MRQ)-990.67%
  • Debt To Equity (MRQ)2.34%

EVENTS

  • Earnings Date03/09/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Brickell Biotech Inc News

There is no recent news for this security.

Latest BBI News From Our Partners

QUOTE FINDER

Profile

MORE
Brickell Biotech, Inc., formerly Vical Incorporated, is a clinical-stage pharmaceutical company that focuses on the development of therapeutics for the treatment of skin diseases. The Company’s pipeline consists of molecular entities targeting the treatment of the indications, such as hyperhidrosis, cutaneous T-cell lymphoma, allergic contact dermatitis, psoriasis and androgenic alopecia. The Company’s product candidates include BBI-3000, BBI-6000 and Sofpironium Bromide....
Reginald Hardy
Chairman
Robert Brown
Chief Executive Officer
Albert Marchio II
Chief Financial Officer
Jose Breton
Chief Accounting Officer
Address
5777 Central Ave Ste 102
Boulder, CO
80301-2870
United States